Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.63 |
| ▸ | FEN1 | P39748 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875717 | 0.83 | HSD17B1 (0.51) | ERCC5FEN1LOXL2KDRLOXL3 | |
| SCHEMBL28207097 | 0.81 | LOXL2 (0.58) | ERCC5FEN1LOXL2KDRCCNE1 | |
| SCHEMBL21812622 | 0.81 | LOXL2 (0.84) | ERCC5FEN1LOXL2KDRLOXL3 | |
| SCHEMBL9665362 | 0.81 | LOXL2 (0.58) | ERCC5FEN1LOXL2KDRCCNE1 | |
| SCHEMBL8830055 | 0.81 | LOXL2 (0.58) | ERCC5FEN1LOXL2KDRCCNE1 | |
| SCHEMBL2226631 | 0.81 | LOXL2 (0.58) | ERCC5FEN1LOXL2KDRCCNE1 | |
| SCHEMBL17014778 | 0.81 | LOXL2 (0.58) | ERCC5FEN1LOXL2KDRCCNE1 | |
| SCHEMBL1198760 | 0.81 | LOXL2 (0.48) | ERCC5FEN1LOXL2CDK2CDK5 | |
| SCHEMBL18211804 | 0.80 | LOXL2 (0.47) | ERCC5FEN1LOXL2KDRLOXL3 | |
| SCHEMBL330645 | 0.79 | LOXL2 (0.57) | ERCC5FEN1LOXL2KDRCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149190-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | claimed |
| US-20170058314-A1 | NOVEL METHODOLOGY FOR IDENTIFYING ANTI-PERSISTER ACTIVITY AND ANTIMICROBIAL SUSCEPTIBILITY FOR BORRELIA BURGDORFERI AND OTHER BACTERIA | ZHANG YING (US) | 2017-03-02 | — | — | US | claimed |
| WO-2015171225-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-11-12 | — | — | WO | claimed |
| EP-3321371-A1 | NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN | Zhang, Ying (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321371-A1 | NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN | Zhang, Ying (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3149190-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170058314-A1 | NOVEL METHODOLOGY FOR IDENTIFYING ANTI-PERSISTER ACTIVITY AND ANTIMICROBIAL SUSCEPTIBILITY FOR BORRELIA BURGDORFERI AND OTHER BACTERIA | ZHANG YING (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2015171225-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | ERCC5 1318/4885FEN1 2698/4885LOXL2 156/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | ERCC5 1318/4885FEN1 2698/4885LOXL2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.